160 related articles for article (PubMed ID: 21667225)
1. The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution.
Chang IW; Lin JW; Wu YT
J Neurooncol; 2011 Dec; 105(3):563-72. PubMed ID: 21667225
[TBL] [Abstract][Full Text] [Related]
2. Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm.
Yang QC; Wang YH; Lin Y; Xue L; Chen YJ; Chen MH; Chen J
Int J Clin Exp Pathol; 2014; 7(7):4204-12. PubMed ID: 25120800
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study.
Chang IW; Hsu CT; Lin JW; Hung CH
Folia Neuropathol; 2013; 51(4):275-82. PubMed ID: 24374955
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of O6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: a clinicopathologic and immunohistochemical study of seven cases at a single institution.
Lin JW; Wu YT; Chang IW
Indian J Pathol Microbiol; 2011; 54(4):683-7. PubMed ID: 22234090
[TBL] [Abstract][Full Text] [Related]
5. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
[TBL] [Abstract][Full Text] [Related]
6. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
7. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
8. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.
Isohookana J; Haapasaari KM; Soini Y; Leppänen J; Karihtala P
Pathol Res Pract; 2018 Jun; 214(6):840-847. PubMed ID: 29735403
[TBL] [Abstract][Full Text] [Related]
9. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).
Viúdez A; Carvalho FL; Maleki Z; Zahurak M; Laheru D; Stark A; Azad NS; Wolfgang CL; Baylin S; Herman JG; De Jesus-Acosta A
Oncotarget; 2016 May; 7(18):24950-61. PubMed ID: 26894863
[TBL] [Abstract][Full Text] [Related]
10. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
11. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Buttarelli FR; Massimino M; Antonelli M; Lauriola L; Nozza P; Donofrio V; Arcella A; Oliva MA; Di Rocco C; Giangaspero F
Childs Nerv Syst; 2010 Aug; 26(8):1051-6. PubMed ID: 20552207
[TBL] [Abstract][Full Text] [Related]
12. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression.
Rahman WF; Rahman KS; Nafi SN; Fauzi MH; Jaafar H
Int J Clin Exp Pathol; 2015; 8(6):6095-106. PubMed ID: 26261487
[TBL] [Abstract][Full Text] [Related]
14. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
15. Predicting O6-Methylguanine-DNA Methyltransferase Protein Expression in Primary Low- and High-Grade Gliomas Using Certain Qualitative Characteristics of Amide Proton Transfer-Weighted Magnetic Resonance Imaging.
Su L; Gao P; Lin S; Wu B; Qin W; Lin Y; Xue J
World Neurosurg; 2018 Aug; 116():e814-e823. PubMed ID: 29803064
[TBL] [Abstract][Full Text] [Related]
16. High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma.
Zhang JF; Chen Y; Lin GS; Zhang JD; Tang WL; Huang JH; Chen JS; Wang XF; Lin ZX
Hum Pathol; 2016 Jun; 52():136-44. PubMed ID: 26980050
[TBL] [Abstract][Full Text] [Related]
17. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
18. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
[TBL] [Abstract][Full Text] [Related]
19. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
[TBL] [Abstract][Full Text] [Related]
20. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
